Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.63 +4.8%	$5.78	$4.65 ▼ $10.24	$94.16M	0.22	71,788 shs	66,802 shs
ENTX Entera Bio	$1.86 -11.0%	$2.00	$1.41 ▼ $2.79	$84.54M	1.47	69,405 shs	52,053 shs
GDTC CytoMed Therapeutics	$2.12 -0.4%	$2.30	$1.20 ▼ $4.05	$23.22M	-0.33	78,386 shs	677 shs
LXEO Lexeo Therapeutics	$3.94 -3.7%	$3.17	$1.45 ▼ $19.50	$130.80M	0.52	524,058 shs	354,940 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	0.00%	-4.25%	-4.09%	-13.25%	-30.41%
ENTX Entera Bio	0.00%	-10.14%	-7.23%	-1.06%	-15.07%
GDTC CytoMed Therapeutics	0.00%	+3.51%	-9.32%	-14.44%	+2.02%
LXEO Lexeo Therapeutics	0.00%	+1.55%	+45.93%	+28.34%	-78.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	2.1704 of 5 stars	3.5	4.0	2.0	0.8	0.0
ENTX Entera Bio	1.866 of 5 stars	3.5	3.0	1.9	0.8	0.0
GDTC CytoMed Therapeutics	2.5949 of 5 stars	3.5	5.0	3.3	0.0	0.0
LXEO Lexeo Therapeutics	3.6614 of 5 stars	4.5	2.0	2.4	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$16.67	196.03% Upside
ENTX Entera Bio	3.00	Buy	$10.00	437.63% Upside
GDTC CytoMed Therapeutics	3.00	Buy	$5.00	135.63% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	321.32% Upside

Current Analyst Ratings Breakdown

Latest GDTC, COYA, ENTX, and LXEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.69M	25.55	N/A	N/A	$2.47 per share	2.28
ENTX Entera Bio	$223K	379.11	N/A	N/A	$0.36 per share	5.17
GDTC CytoMed Therapeutics	$69.50K	334.02	N/A	N/A	$0.78 per share	2.72
LXEO Lexeo Therapeutics	$650K	201.22	N/A	N/A	$4.26 per share	0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$7.99M	-$1.07	N/A	N/A	N/A	N/A	-31.63%	-27.76%	8/11/2025 (Estimated)
ENTX Entera Bio	-$8.89M	-$0.26	N/A	N/A	N/A	N/A	-107.24%	-92.29%	8/8/2025 (Estimated)
GDTC CytoMed Therapeutics	-$3.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/28/2025 (Estimated)
LXEO Lexeo Therapeutics	-$66.39M	-$3.30	N/A	N/A	N/A	N/A	-57.66%	-48.18%	8/11/2025 (Estimated)

Latest GDTC, COYA, ENTX, and LXEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/9/2025	Q1 2025	ENTX Entera Bio	-$0.07	-$0.06	+$0.01	-$0.06	N/A	$0.04 million
3/28/2025	Q4 2024	ENTX Entera Bio	-$0.08	-$0.06	+$0.02	-$0.06	$0.04 million	$0.04 million
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.31	15.31
ENTX Entera Bio	N/A	6.61	6.61
GDTC CytoMed Therapeutics	0.04	21.54	N/A
LXEO Lexeo Therapeutics	0.01	5.95	5.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
ENTX Entera Bio	14.11%
GDTC CytoMed Therapeutics	0.04%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
ENTX Entera Bio	10.90%
GDTC CytoMed Therapeutics	N/A
LXEO Lexeo Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
ENTX Entera Bio	20	45.45 million	31.88 million	Optionable
GDTC CytoMed Therapeutics	N/A	10.94 million	N/A	Not Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.58 million	Not Optionable

GDTC, COYA, ENTX, and LXEO Headlines

Recent News About These Companies

Lexeo Therapeutics files to sell 41.63M shares of common stock for holders

June 13 at 7:43 PM | msn.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLC

June 6, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $10.00 at JPMorgan Chase & Co.

May 31, 2025 | marketbeat.com

Leerink Partnrs Issues Positive Forecast for LXEO Earnings

May 31, 2025 | marketbeat.com

Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares

May 29, 2025 | nasdaq.com

Lexeo raises $80 million to shore up gene therapy work after layoffs

May 28, 2025 | thepharmaletter.com

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

May 27, 2025 | globenewswire.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by Brokerages

May 24, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Trims Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

May 23, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Lifted by Point72 Asset Management L.P.

May 22, 2025 | marketbeat.com

Vestal Point Capital LP Raises Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for LXEO Issued By HC Wainwright

May 21, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Lifted by Janus Henderson Group PLC

May 17, 2025 | marketbeat.com

Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating

May 16, 2025 | tipranks.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.61%

May 15, 2025 | aaii.com

Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

May 15, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Omega Fund Management LLC

May 15, 2025 | marketbeat.com

Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies

May 12, 2025 | fiercebiotech.com

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

May 12, 2025 | globenewswire.com

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

May 5, 2025 | seekingalpha.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Up 9.41%

May 2, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC, COYA, ENTX, and LXEO Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.63 +0.26 (+4.84%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.60 -0.03 (-0.53%)

As of 06/13/2025 04:04 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Entera Bio NASDAQ:ENTX

$1.86 -0.23 (-11.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.86 0.00 (0.00%)

As of 06/13/2025 04:04 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

CytoMed Therapeutics NASDAQ:GDTC

$2.12 -0.01 (-0.38%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$2.13 +0.01 (+0.38%)

As of 06/13/2025 07:59 PM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Lexeo Therapeutics NASDAQ:LXEO

$3.94 -0.15 (-3.67%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.14 +0.20 (+5.08%)

As of 06/13/2025 07:43 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time